Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission

AIDS

Volumn 10, Issue 3, 1996, Pages 273-282

  Rodriguez, Evelyn M ^a,m   Mofenson, Lynne M ^b   Chang, Bei Hung ^c   Rich, Kenneth C ^d   Fowler, Mary Glenn ^e   Smeriglio, Vincent ^f   Landesman, Sheldon ^g   Fox, Harold E ^h,l   Diaz, Clemente ⁱ   Green, Karen ^j   Hanson, I Celine ^k  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h New York State Psychiat Inst and New York Presbyterian Hospital Columbia University Medical Center   (United States)

ⁱ UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^j UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l GEORGE WASHINGTON UNIVERSITY   (United States)

^m Bureau of Health Resources Delivery   (United States)

more..

Author keywords

Gynecology; Obstetrics; Pediatrics; Pregnancy; Prenatal drug use; Risk factors; Vertical HIV transmission; Women

Indexed keywords

CD4 ANTIGEN; COCAINE; DIAMORPHINE; METHADONE; OPIATE; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; DELIVERY; DRUG ABUSE; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MEMBRANE RUPTURE; MULTIVARIATE ANALYSIS; NEWBORN; PERINATAL INFECTION; PREGNANCY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SELF REPORT; T LYMPHOCYTE; UNITED STATES; URINALYSIS; VIRUS TRANSMISSION;

EID: 9044250488     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199603000-00006     Document Type: Article

References (44)

1. Centers tor Disease Control and Prevention: HIV/AIDS Surveillance Report (Vol 6 No 2). Atlanta: Centers for Disease Control; 1994:1-39.
2. Lyman WD: Perinatal AIDS: drugs of abuse and transplacental infection. In Drugs of Abuse, Immunity and AIDS. Edited by Friedman H, Klein TW, Specter S. New York: Plenum Press; 1993.
3. Rodriguez EM, Vermund SH: Maternal drug use and pediatric HIV infection: a methodologic review. Pediatr AIDS HIV Infect 1991, 3:107-122.
4. European Collaborative Study Group: Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 1991, 337:253-260.
5. Blanche S, Rouzioux C, Moscato ML, et al.: A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. N Engl J Med 1989, 320:1643-1648.
6. Landesman SH, Burns D, Kalish L, et al.: Increased duration of rupture of membranes (ROM) is associated with an increased risk of perinatal HIV-1 transmission. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, October 1994 [abstract I 19].
7. Landesman SH, Burns D, Kalish LA, et al. Obstetrical factors and vertical transmission of HIV-1: role of duration of ruptured membranes. N Engl J Med (in press).
8. Rodriguez EM, Mendez H, Rich K, et al.: Maternal drug use in perinatal HIV studies: the Women and Infants Transmission Study. In Pediatric AIDS: Clinical, Pathological and Basic Science Perspective. Edited by Lyman WD, Rubinstein A. New York: The New York Academy of Sciences; 1993:123.
9. Stratton P, Rich K, Tuomala R, et al.: Maternal CD4 counts of HIV+ women as a predictor of newborn outcomes. 32nd Interscience Conference on Antimnrobial Agents and Chemotherapy. Anaheim, October 1992 [abstract 598].
10. Pitt J, Landay A, McIntosh K, et al.: Prenatal maternal circulating leukocyte HIV predisposes to HIV culture positivity in their infants: progress report from a North American cohort. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, October 1992 [abstract 599].
11. Peterson PK, Gekker G, Chao CC, Schut R, Molitor TW, Balfour HH: Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures - involvement of transforming growth factor-β. J Immunol 1991, 146:81-84.
12. Bagasra O, Pomerantz RJ: Human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells in the presence of cocaine. J Infect Dis 1993,168:1157-1164.
13. Peterson PK, Sharp B, Gekker G, Portoghese PS, Sannerud K, Balfour HH: Morphine potentiates the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. J Acquir Immune Defic Syndr 1990, 4:869-873.
14. Baseit R: Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology. Davis: Biomedical Publications; 1980:89-90.
15. McIntosh K, Pitt J, Brambilla D, et al.: Blood culture in the first six months of life for the diagnosis of vertically transmitted human immunodeficiency virus infection. J Infect Dis 1994, 170:996 1000.
16. Hollinger FB, Bremer JW, Myers LE, Gold JWM, McQuay L and the NIH/NIAID/DAIDS/ACTG Virology Laboratories: Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS clinical trials group. J Clin Microbiol 1992, 30:1787-1794.
17. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J: Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 1993, 14:702-715.
18. Cleveland WS: Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979, 74:829-836.
19. SAS Institute: SAS/STAT User's Guide, Version 6, 4th Edn, Vol 1 & 2. Cary: SAS Institute, Inc.; 1990.
20. Pitt J, Landay A, McIntosh K, et al.: Maternal CD4% and viral culture positivity interact to influence the risk of maternal-fetal HIV transmission. 1st National Conference on Human Retroviruses and Related Infections. Washington, DC, December 1993 [abstract 671].
21. Goedert JJ, Mendez H, Drummond JE, et al.: Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet 1989, ii:1351-1354.
22. European Collaborative Study: Risk factors for mother-to-child transmission of HIV-1. Lancer 1992, 339:1007-1012.
23. Alcabes P, Friedland G: Injection drug use and human immunodeficiency virus infection. Clin Infect Dis 1995, 20:1467-1479.
24. Hague RA, Mok JYQ, Johnstone FD, et al.: Maternal factors in HIV transmission. Int J STD AIDS 1993, 4:142-146.
25. Burns DN, Landesman S, Muenz LR, et al.: Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4+ levels. J Acquir Immune Defic Syndr 1994, 7:718-726.
26. Mayaux M-J, Blanche S, Rouzioux C, et al.: Maternal factors associated with perinatal HIV-1 transmission: the French Cohort Study: 7 years of follow-up observation. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:188-194.
27. Nair P, Alger L, Hines S, Seiden S, Hebel R, Johnson JP: Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. J Acquir Immune Defic Syndr 1993, 6:298-302.
28. Nesheim SR, Lindsay M, Sawyer MK, et al.: A prospective population-based study of HIV perinatal transmission. AIDS 1994, 8:1293-1298.
29. Fanning T, Krasinski K, Chiarella J, Turner BJ: Risk of HIV-related symptoms in 40 sets of twins: a population-based analysis. X International Conference on AIDS. Yohohoma, August 1994 [abstract PC0153].
30. Tibaldi C, Ziarati N, Salassa B, D'Ambrosio R, Sinicco A: Asymptomatic women at high risk of vertical HIV-1 transmission to their fetuses. Br J Obstet Gynecol 1993, 100:334-337.
31. Borkowsky W, Krasinski K, Cao Y, et al.: Correlation of perinatal transmission of human immunodeficiency virus type 1 with maternal viremia and lymphocyte phenotypes. J Pediatr 1994, 125:345-351.
32. Farley JJ, Bauer G, Johnson JP, Cole GA: Phytohemagglutinin-inducible p24 in peripheral blood mononuclear cells as a predictor of human immunodeficiency virus type 1 vertical transmission and infant clinical status. Pediatr Infect Dis J 1994, 13:1079-1082.
33. Weiser B, Nachman S, Tropper P, et al.: Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci USA 1994, 91:8037-8041.
34. Sastry BV: Placenta! toxicology: tobacco smoke, abused drugs multiple chemical interactions and placental function. Reprod fertil Dev 1991, 3:355-372.
35. Rosenak D, Diamant YZ, Yaffe H, Hornstein E: Cocaine: maternal use during pregnancy and its effect on the mother, fetus and the infant. Obstet Cynecol Survey 1990, 45:348-359.
36. Klein TW, Newton CA, Friedman H: Suppression of human and mouse lymphocyte proliferation by cocaine. Adv Biochem Psychopharmacol 1988, 44:139-146.
37. Bagasra O, Forman IJ: Functional analysis of lymphocyte subpopulations in experimental cocaine abuse: dose-dependent activation of lymphocyte subsets. Clin Exp Immunol 1989, 77:289-293.
38. Peterson PK, Sharp B, Gekker G, Brummit C, Keane WF: Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J Immunol 1987, 138:3907-3912.
39. Centers for Disease Control and Prevention: Update: AIDS among women - United States, 1994. MMWR 1995, 44:81-84.
40. Rosenblum LS, Buehler JW, Morgan MW, et al.: Drug dependence: a leading diagnosis in hospitalized HIV-infected women. J Women's Health 1993, 2:35-40.
41. Cowan DN, Brundage JF, Pomerantz RS: HIV infection among women in the army reserve components. J Acquir Immune Defic Syndr 1994, 7:171-176.
42. Mofenson LM: Epidemiology and determinants of vertical HIV transmission. Semin Pediatr Infect Dis 1994, 5:252-255.
43. Committee on Obstetrics: Maternal and Fetal Medicine. ACOG Committee Opinion: Cocaine in pregnancy (Document No. 114). Washington, DC: American College of Obstetricians and Gynecologists; 1992:1-4
44. Centers for Disease Control and Prevention: Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994, 43 (suppl RR-11):1-20.